Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group

Bicara Therapeutics (NASDAQ:BCAX) had its price objective raised by research analysts at The Goldman Sachs Group from $14.00 to $16.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would indicate a potential downside of 17.81% from the stock’s current price.

A number of other brokerages have also recently issued reports on BCAX. Bank of America began coverage on shares of Bicara Therapeutics in a report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 target price on the stock. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday. Wells Fargo & Company increased their target price on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Citigroup began coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating on the stock. Finally, BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.00.

Bicara Therapeutics Trading Up 2.2%

Bicara Therapeutics stock traded up $0.43 during mid-day trading on Tuesday, reaching $19.47. The company’s stock had a trading volume of 265,308 shares, compared to its average volume of 511,626. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -8.69 and a beta of -0.78. The business has a 50 day moving average price of $17.15 and a 200-day moving average price of $16.61. Bicara Therapeutics has a twelve month low of $7.80 and a twelve month high of $20.25.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04. On average, equities analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Claire Mazumdar sold 1,596 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20. Following the transaction, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at approximately $6,431,478.40. This trade represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $18.52, for a total transaction of $170,384.00. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,691,974.60. This represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 137,969 shares of company stock valued at $2,586,198 in the last quarter.

Institutional Trading of Bicara Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bleakley Financial Group LLC acquired a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $481,000. Cantor Fitzgerald L. P. bought a new position in Bicara Therapeutics during the 3rd quarter valued at $1,579,000. Schroder Investment Management Group increased its position in shares of Bicara Therapeutics by 921.0% during the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after purchasing an additional 383,681 shares during the period. Skandinaviska Enskilda Banken AB publ increased its position in shares of Bicara Therapeutics by 160.9% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock valued at $922,000 after purchasing an additional 61,201 shares during the period. Finally, SCS Capital Management LLC bought a new stake in shares of Bicara Therapeutics in the 2nd quarter worth $496,000.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $42 and reaffirmed a “buy” rating — a very bullish valuation (≈120% upside from the earlier reference price). HC Wainwright PT Raise
• Positive Sentiment: Citizens / JMP reaffirmed a “market outperform” rating and set a $31 target (~63% upside), signaling continued institutional confidence in Bicara’s clinical roadmap. Citizens JMP Note
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating with a $30 target (~57% upside), reinforcing bullish analyst sentiment behind the shares. Wedbush Note
• Positive Sentiment: Q4 results beat estimates: Bicara reported EPS of ($0.68) vs. consensus ($0.72) and provided a business update that selected 1,500 mg weekly ficerafusp alfa as the optimal dose and initiated the Phase 3 FORTIFI‑HN01 pivotal trial; interim analysis expected mid‑2027 — material clinical progress that supports upside. Press Release
• Neutral Sentiment: The Q4 earnings call transcript and slide deck are available for details on cash position, timelines and trial design; these documents help investors assess runway and milestones but contain no surprise headlines. Earnings Call Highlights
• Negative Sentiment: Wells Fargo raised its target to $16 but set an “equal weight” rating — the $16 target sits below recent trading levels and implies downside, introducing a more cautious institutional view. Wells Fargo Note
• Negative Sentiment: Insider selling: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, trimming her direct holdings by ~2.4%. Insider sales can be interpreted negatively even if routine (diversification/liquidity). Insider Sale

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.